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Comparison of ability of protein kinase C inhibitors to arrest cell growth
and to alter cellular protein kinase C localisation
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Medical Research Council Toxicology Unit, Centrefor Mechanisms ofHuman Toxicity, University ofLeicester, Lancaster Road,
PO Box 138, Leicester LE] 9HN, UK.
Summary Inhibitors of protein kinase C (PKC) such as the staurosporine analogues UCN-01 and CGP
41251 possess antineoplastic properties, but the mechanism of their cytostatic action is not understood. We
tested the hypothesis that the ability of these compounds to arrest growth is intrinsically linked with their
propensity to inhibit PKC. Compounds with varying degrees of potency and specificity for PKC were
investigated in A549 and MCF-7 carcinoma cells. When the log values of drug concentration which arrested
cell growth by 50% (IC50) were plotted against the logs of the IC5n values for inhibition of cytosolic PKC
activity, two groups of compound could be distinguished. The group which comprised the more potent
inhibitors of enzyme activity (calphostin C, staurosporine and its analogues UCN-01, RO 31-8220, CGP
41251) were the stronger growth inhibitors, whereas the weaker enzyme inhibitors (trimethylsphingosine,
miltefosine, NPC-15437, H-7, H-7I) affected proliferation less potently. GF 109203X was exceptional in that it
inhibited PKC with an IC5o in the 10-8 M range, yet was only weakly cytostatic. To substantiate the role of
PKC in the growth inhibition caused by these agents, cells were depleted of PKC by incubation with
bryostatin 1 (1 jsM). The susceptibility of these enzyme-depleted cells towards growth arrest induced by
staurosporine, RO 31-8220, UCN-01 or H-7 was studied. The drug concentrations which inhibited incorpora-
tion of [3H]thymidine into PKC-depleted A549 cells by 50% were slightly, but not significantly, lower than
those observed in control cells. These results suggest that PKC is unlikely to play a direct role in the arrest of
the growth of A549 and MCF-7 cells mediated by these agents. Staurosporine is not only a strong inhibitor of
PKC but also mimics activators of this enzyme in that it elicits the cellular redistribution of certain PKC
isoenzymes. The ability of kinase inhibitors other than staurosporine to exert a similar effect was investigated.
Calphostin C, H-7, H-71, miltefosine, staurosporine, UCN-01, RO 31-8220, CGP 41251 or GF 109203X were
incubated for 30 min with A549 cells in the absence or presence of the PKC activator 12-O-tetradecanoyl
phorbol-13-acetate. The subcellular distribution of PKC-z-, -e and -< was measured by Western blot analysis.
None of the agents affected PKC-x or -4. UCN-01, RO 31-8220 and GF 109203X (0.1-1 tsM) mimicked
staurosporine by causing the cellular translocation ofPKC-e, whereas calphostin C, CGP 41251, H-7, H-71 or
miltefosine did not alter the cellular localisation of this PKC isoenzyme. According to these results, transloca-
tion of certain PKC isoenzymes is not only a consequence of PKC activation but, in the case of selected
staurosporine analogues, also of PKC inhibition.
Keywords: cytostasis; protein kinase C inhibitors; staurosporine analogues; adenocarcinoma cells
Protein kinases such as the serine- and threonine-specific
enzyme family protein kinase C (PKC) are essential elements
in the transduction of cellular signals elicted by growth fac-
tors and hormones, and they play a pivotal role in the
regulation ofcell differentiation and proliferation (Nishizuka,
1992). Not surprisingly therefore, they are prominent targets
for the design of novel anti-cancer drugs. Pharmacological
interference with PKC seems a logical therapeutic strategy
because in certain experimental neoplasias altered PKC func-
tion or expression have been linked to malignant transforma-
tion (Cacace et al., 1993; Mischak et al., 1993). Modulators
of PKC activity are currently under clinical evaluation, and
the results of two phase I trials of the PKC activator bryo-
statin 1 have recently been published (Phillip et al., 1993;
Prendiville et al., 1993). The dose-limiting toxicity of bryo-
statin 1 was myalgia, and in one of the trials the drug
exhibited activity against malignant melanoma (Phillip et al.,
1993). Numerous inhibitors ofPKC have been described, and
most of them possess cytostatic and cytotoxic properties
(Tamaoki and Nakano, 1990). They may also be useful in
therapy as synergistic enhancers of the antitumour activity of
conventional cytotoxic anti-cancer drugs (Posada et al., 1989;
Sato et al., 1990; Utz et al., 1994) and as inhibitors of
tumour cell invasion (Schwartz et al., 1993). Most of these
molecules are only modestly selective inhibitors of PKC and
affect a variety of kinases. For example, the microbial pro-
duct staurosporine is a potent, but non-selective, kinase
inhibitor. Two analogues with higher specificity for PKC,
UCN-01 and CGP 41251, have shown significant anti-
tumour activity in vivo (Meyer et al., 1989; Akinaga et al.,
1991). Both of these drugs are in preparation for phase 1
clinical evaluation as anti-cancer drugs, the former in Japan
and the United States and the latter in Europe. In the work
described here the hypothesis was tested that inhibition of
PKC is related to inhibition of cell growth. Several PKC
inhibitors of diverse chemical structure (Figure 1) were
assessed for their ability to interfere with PKC activity and
proliferation in two human-derived carcinoma cell lines. Fur-
thermore, their effect on the growth of cells which had lost
PKC activity via enzyme down-regulation was studied.
Paradoxically staurosporine is not only an effective inhibi-
tor of PKC but it also shares certain properties with
activators of this enzyme (Dlugosz and Yuspa, 1991). In
most cell types PKC is contained predominantly in the cyto-
sol and its activation engenders alterations in the subcellular
localisation of the enzyme. Activator-induced translocation
of PKC is thought to position the enzyme in close proximity
to its physiologically important-substrates. For example, in
human A549 lung and MCF-7 breast carcinoma cells the
tumour promoter 12-0-tetradecanoyl phorbol-13-acetate
(TPA) and the experimental anti-tumour agent bryostatin 1
provoke the rapid redistribution of PKC from the cytosol to
the particulate and nuclear fractions (Issandou et al., 1988;
Dale et al., 1989). Intriguingly, staurosporine can also cause
PKC translocation. In GH4C1 rat pituitary cells it has been
shown to elicit the redistribution of the PKC isoenzymes a
and a from the cytosol to the membrane (Kiley et al., 1992).
Furthermore, staurosporine has been found to augment the
TPA-induced translocation of PKC-o to the membrane
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(Bradshaw et al., 1992). In view of these findings we wished
to elucidate whether the effect on the subcellular localisation
of PKC is a general feature of PKC inhibitors or a specific
property of staurosporine. To answer this question the effect
of a series of diverse kinase inhibitors on the localisation of
the PKC isoenzymes contained in A549 cells was investigat-
ed. The agents tested include H-7, its positional isomer H-71
and the staurosporine analogues UCN-01, CGP 41251, RO
31-8220 and GF 109203X, which are thought to inhibit PKC
at the catalytic domain, and the regulatory domain inhibitors
calphostin C and miltefosine. The overall aim of the study
was to increase the understanding of the way in which
different PKC inhibitors interact with tumour cells and to
explore the role which this class of agent may play in cancer
therapy.
Materials and methods
Drugs and reagents
RO 31-8220, CGP 41251, NPC 15437, trimethylsphingosine,
UCN-01, miltefosine and bryostatin 1 were provided by
Roche Research Centre (Welwyn Garden City, UK), Ciba
Geigy (Basle, Switzerland), Nova Pharmaceutical (Baltimore,
MD, USA), Biomembranes Institute (Seattle, WA, USA),
Kyowa Hakko Kogyo (Tokyo, Japan), Asta Pharma (Frank-
furt, Germany) and Cancer Research Institute, Arizona State
University (Tempe, AR, USA) respectively. Calphostin C,
H-7 and GF 109203X were acquired from Calbiochem-Nova-
biochem (Nottingham, UK). Other chemicals and reagents
including staurosporine, H-7I and TPA were purchased from
Sigma (Poole, UK) and 3H-labelled thymidine ([3H]Tdr) from
Amersham International (Amersham, UK). Stock solutions
of NPC 15437, trimethylsphingosine and H-7 were prepared
in water, those of other kinase inhibitors, TPA and bryo-
statin in dimethyl sulphoxide (DMSO), and stored at -20C.
The final concentration of DMSO in the medium did not
exceed 0.3%, which on its own did not affect cell growth. A
monoclonal antibody against PKC-a was purchased from
Tissue Culture Services Biologicals (Botolph Claydon, UK).
The polyclonal antibody against PKC-4 and its antigenic
peptide was acquired from Gibco BRL (Paisley, UK) and a
polyclonal antibody against PKC-e was provided by Dr P
Parker (ICRF Laboratories, London, UK).
Cellgrowth
Human A549 lung and MCF-7 breast carcinoma cells were
obtained from the European Collection of Animal Cell Cul-
tures (Salisbury, UK). Cells (passage number 10-30) were
cultured in an atmosphere of 5% carbon dioxide, the former
in Ham's F-12 medium with penicillin/streptomycin, the lat-
ter in minimum essential medium (Eagle's modification) with
additional pyruvate (1 mM) and non-essential amino acids.
Both media were supplemented with 10% FCS (Imperial
Laboratories Europe, Andover, UK, and Gibco) and gluta-
mine (2 mM). Cells were subcultured routinely twice weekly
to maintain logarithmic growth. For cell proliferation studies
cells were seeded at a density of 1.3 x 104cm-2 and incubat-
ed with 3 ml of medium including agents, which was replen-
ished at intervals of 48 h (A549) or 72 h (MCF-7). Following
incubation for 4 days (A549) or 6 days (MCF-7) with drugs,
cell number was assessed using a Coulter Counter Model
ZM. In order to achieve PKC depletion, cells seeded at
1-2 x 105 per well (3.5 cm diameter) were incubated for 24 h
with bryostatin 1 (1 tLM). Under these conditions growth
inhibition caused by bryostatin 1 is negligible (Dale and
Gescher, 1989; Stanwell et al., 1994). Bryostatin was removed
by extensive washing of the cells followed by a 2 h recovery
period. In previous work using the A549 cell line this wash-
ing procedure has been shown to eliminate bryostatin-medi-
ated effects. The cells were then incubated for a further 24 h
with staurosporine, RO 31-8220, UCN-01 or H-7. In some
experiments cells were incubated with inhibitor for 48 rather
than 24 h, in this case bryostation was not removed and left
in the incubate. After removal of agents inhibition of DNA
synthesis was evaluated by measurement of [3H]Tdr incor-
poration into cells as described previously (Dale and Ges-
cher, 1989). Radioactivity was counted using a Packard 1500
Tricarb scintillation counter.
Measurement ofPKC activity
Cytosol was prepared as described previously (Dale et al.,
1989), and aliquots were placed with kinase inhibitor at
appropriate concentrations in microplate wells. PKC activity
was measured via the incorporation of the y-phosphate
moiety of [32P]ATP into a PKC-specific peptide using a kit
from Amersham International. The value obtained with this
kit is the sum of activities of phospholipid-dependent, Ca2+-
dependent and -independent PKC isoenzymes which are
activated by phorbol esters.
Preparation ofcellularfractions and Western blot analysis
Cytosolic, particulate (which contains membranes, cyto-
skeleton and cell organelles) and nuclear fractions of cells
were obtained essentially as described before (Greif et al.,
1992) with some modifications (Stanwell et al., 1994). Protein
content of the fractions was measured by the Bradford assay
(Bradford, 1976). Western blot analysis was performed as
described previously (Stanwell et al., 1994). The amount of
protein loaded per lane was 20 tg for detection of cPKC-oc
and 30 lg for nPKC-e. Detection was by enhanced chemi-
luminescence generated by oxidation of luminol in the
presence of hydrogen peroxide using an ECL kit from Amer-
sham International. Immunoreactivity was quantitated using
Molecular Dynamics Computing Densitometer, and the
values shown in Figures 4 and 5 are expressed as a percen-
tage of the sum of immunoreactive protein in all three frac-
tions. The significance of differences in band intensity was
evaluated by Student's t-test.
Results
Relationship between inhibition ofPKC and inhibition ofcell
growth
Nine PKC inhibitors, staurosporine (Tamaoki et al., 1986),
UCN-01 (Takahashi et al., 1987), RO 31-8220 (Davis et al.,
1992), CGP 41251 (Meyer et al., 1989), GF 109203X (Toullec
et al., 1991), calphostin C (Kobayashi et al., 1989), milte-
fosine (Uberall et al., 1991), NPC-15437 (Sullivan et al.,
1991) and H-7 (Hidaka et al., 1984) (for structures see Figure
1), were investigated for their ability to inhibit cell growth
and PKC activity isolated from the cytosol of two carcinoma
cell lines. In the case of the A549 cells, two further agents,
trimethylsphingosine (Endo et al., 1991) and H-71, a posi-
tional isomer of H-7, were included. Of these agents stauros-
porine and calphostin C inhibited growth most effectively in
both cell types (Table I). Staurosporine and its analogues
were the most potent inhibitors of PKC activity. H-7I was
the least effective inhibitor ofcell growth and PKC activity in
A549 cells. When the logs of the ICo values obtained for
PKC inhibition were plotted against the logs of the ICm
values for growth arrest (Figure 2) two groups of compound
could be distinguished. The group which comprised the more
potent inhibitors of PKC activity, i.e. staurosporine, UCN-
01, RO 31-8220, CGP 41251 and calphostin C, were also the
stronger growth inhibitors with IC50 values of <1 gM. Of the
stronger PKC inhibitors used here, GF 109203X behaved
exceptionally, in that it interfered with cell growth only
weakly, with an ICm of >7jAM. Trimethylsphingosine, milte-
fosine, NPC-15437, H-7 and H-7I displayed IC50 values for
PKC inhibition in the 10-100tM range. They arrested
growth at concentrations of > 1 riM. When a line of best fit
was computed from the logarithmic plot it was characterised
by correlation coefficients of r = 0.64 for A549 and r = 0.59for MCF-7 cells. These results suggest that the ability of
these agents to arrest cell growth is not reflected by their
capability to inhibit PKC. Nevertheless, this conclusion has
to be interpreted with caution in view ofdifferences in design
between the two experiments, in that the effect of the com-
pounds on proliferation was assessed in intact cells, whereas
enzyme inhibition was measured in cytosolic extracts in vitro.
Growth arrest in PKC-depleted cells
To define more precisely the role which PKC might play in
growth arrest caused by these agents, their effect on cells with
down-regulated PKC was investigated. The hypothesis tested
in this experiment was that, if inhibition of PKC mediates
growth arrest, then PKC-depleted cells should be less suscep-
tible towards the cytostatic potential of these agents than
PKC-proficient naive cells. Cells were exposed for 24h to
bryostatin 1 at 1 riM, which caused the complete down-
regulation of conventional (c) PKC-o and novel (n) PKC-c
as assessed by Western blot analysis (Stanwell et al., 1994).
Subsequently cells were washed and incubated with stauros-
porine, RO 31-8220, UCN-01 or H-7 for 24h. Their pro-
liferative competence was adjudged by measurement ofincor-
poration of [3H]Tdr into cells. PKC remained undetectable
by immunoblotting for up to 30 h following the removal of
bryostatin. Figure 3 shows that treatment of A549 cells with
bryostatin did not decrease the degree to which DNA syn-
thesis was inhibited by either the general kinase inhibitor
staurosporine or the PKC-specific agent RO 31-8220. In fact,
the bryostatin-treated cells were consistently, albeit weakly,
more sensitive towards the effect of the kinase inhibitors than
naive cells. The IC,3 values obtained for staurosporine, RO
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31-8220, UCN-01 and H-7 in PKC-depleted cells were
0.5nM, 1.6I1M, 47 nM and 201M respectively. The corre-
sponding values determined in these experiments in control
cells were 1.2 nM, 1.9JM, 68 nM and 32gsM respectively. The
IC50 values determined by this method for the staurosporine
analogues are about twice the IC50 values provided by cell
counting (see Table I). This discrepancy is probably due to
differences in procedures between the two experiments, par-
ticularly with regard to exposure time and seeding density.
Cells responded similarly to GF 109203X, which, like RO
31-8220, is a PKC-specific bisindolylmaleimide analogue of
staurosporine (Toullec et al., 1991). Likewise, in parallel
experiments PKC-depleted MCF-7 cells did not markedly
differ from control MCF-7 cells in sensitivity towards kinase
inhibitors (results not shown). In order to rule out the pos-
sibility that the incubation time was insufficient for the kinase
inhibitors to exert maximal growth-inhibitory potency, the
experiment was repeated and the cells were exposed to
staurosporine or RO 31-8220 for 48 h rather than 24 h with
bryostatin present in the incubate for the duration of the
entire experiment. The IC50 values determined in these
experiments are similar to those described above. Also, under
these conditions the sensitivity of the PKC-depleted cells
towards the growth-arresting potential of the kinase inhibi-
tors was slightly increased compared with that of their PKC-
proficient counterparts (results not shown), analogous to the
observation made in the 24 h exposure study.
Effect ofPKC inhibitors on PKC isoenzyme localisation
Cells were incubated for 30min with staurosporine (1 nm to
1 ILM), UCN-01, RO 31-8220, CGP 41251, GF 109203X (all
0.1 and 1 EiM), calphostin C (0.5I1M), miltefosine (20011M),
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H-7 or H7-I (both 0.5 mM) in the presence or absence of
TPA (25 nM). Cellular fractions were prepared, and levels of
PKC isoenzymes were determined by Western blot analysis
using a monoclonal anti-PKC-o antibody and polyclonal
antibodies against PKCs-e and -<. Our previous studies have
shown that these three PKC isoenzymes are abundantly ex-
pressed in A549 cells (Stanwell et al., 1994).
Consistent with its ability to attenuate the TPA-mediated
change in distribution of phorbol ester binding sites (Brad-
shaw et al., 1992), staurosporine increased TPA-induced
translocation of cPKC-c. Although the effect was not
significant, as deduced from the densitometry readings, a
definite trend was observed (P= 0.08) (Figure 4). One other
agent, UCN-01 at 1 JAM, behaved similarly. However, results
with UCN-01 were inconsistent, as it augmented TPA in only
three out of six blots. The staurosporine analogues CGP
41251, RO 31-8220 and GF 109203X, like calphostin C,
miltefosine, H-7 and H-7I, failed to affect TPA-induced
cPKC-a redistribution. None of the inhibitors changed TPA-
induced relocalisation of nPKC-e. However, when stauros-
porine, UCN-01, RO 31-8220 and GF 109203X were incub-
ated with cells on their own, they caused the redistribution of
nPKC-s from the cytosol to the particulate and nuclear
fractions (Figure 5). Staurosporine was the most potent
Table I Inhibition of PKC and growth ofA549 and MCF-7 cells by kinase inhibitors
IC50 PKC (LM) IC50 Growth (JAM)
Compound A549 MCF-7 A549 MCF-7
Ro 31-8220 0.023±0.004 0.048±0.0058 0.780±0.04 0.897±0.013
GF 109203X 0.026±0.004 0.021 ±0.004 7.6±0.5 7.3±0.9
UCN-01 0.033±0.007 0.0178±0.002 0.034±0.002 0.0175±0.001
Staurosporine 0.066±0.003 0.0163±0.0045 0.00065±0.00005 0.0032±0.0001
CGP 41251 0.079±0.007 0.044±0.006 0.082±0.01 0.097±0.012
Calphostin C 0.487±0.062 1.09±0.18 0.001±0.00013 0.00092±0.00011
TMS 38.00±2.00 ND 3.10±0.20 ND
NPC 15-437 39.00±5.00 43.30±6.90 4.30±0.10 3.70±0.10
H-7 55.00±5.00 54.30±7.50 29.00±2.00 21.30± 1.50
Miltefosine 57.00±16.00 577.00±29.00 24.00±1.00 44.00±0.50
H-71 99.00±0.30 ND 262.00±26.00 ND
-IC50PKC, 50% inhibitory concentration for PKC activity. Cytosolic PKC was measured using a
PKC-specificpeptidesubstratefromAmershamInternational.bIC_G,h,50% inhibitoryconcentration
forgrowth. Cellswerecountedfollowingexposure tothedrugsfor4(A549) or6days(MCF-7). ND, not
determined.
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Figure 2 Relationship between the ability of compounds to
arrest cell growth and to inhibit cytosolic PKC activity in A549
(a) and MCF-7 cells (b). Points are the mean of three experi-
ments, each conducted in duplicate. For details of growth condi-
tions and PKC assay see the Materials and methods section.
Abbreviations are as explained in the legend to Figure 1.
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Figure 3 Effect of staurosporine (a) and RO 31-8220 (b) on
incorporation of [3H]Tdr into naive A549 cells (0) and PKC-
depleted A549 cells (0). cPKC-a and nPKC-s were completely
down-regulated by incubation with bryostatin I (1 JAM) for 24 h.
Subsequently cells were exposed to kinase inhibitors for a further
24 h period. Results are the mean ± s.d. of three experiments,
each conducted in duplicate. For details of the assay see the
Materials and methods section.
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Figure 4 Western blot analysis of cPKC-a (a) and quantitation
by laser densitometry of cPKC-a protein (b) in cytosolic (C),
particulate (P) and nuclear (N) fractions from naive A549 cells
(control) and cells which have been incubated for 30min with
TPA (25 nM) or staurosporine (1pM) alone, or TPA together
with staurosporine, UCN-01, RO 31-8220, GF 109203X or CGP
41251 (all 1 llM). The blot obtained with staurosporine alone is
representative of those obtained with the other inhibitors in the
absence of TPA (results not shown). Arrow indicates position of
cPKC-x protein. For details of the assay see Materials and
methods section. For abbreviations see legend to Figure 1. Values
in b, which are expressed as percentage of the sum of
immunoreactive protein in all three fractions, are the mean ± s.d.
of three separate blots. cPKC-a levels in subfractions of cells
incubated with TPA and either calphostin C (0.5l4M), H-7, H-71
(both 500pM) or miltefosine (2001M) were not different from
those shown with TPA alone (results not shown).
translocating agent, with a slight effect observed at 1 and
10 nM (result not shown). For all four agents the effect was
noticeable at 0.1 AM and strong at 1 JAM. Thus, except in the
case of staurosporine, the concentrations required to elicit
nPKC-c translocation were considerably greater than those
which caused PKC inhibition (see Table I). CGP 41251,
calphostin C, miltefosine, H-7 or H7-I did not alter nPKC-c
localisation. The intracellular distribution of the third PKC
isoenzyme expressed in A549 cells, PKC-? (Stanwell et al.,
1994), was not affected by any of the inhibitors.
Discussion
The finding that PKC inhibitors possess antiproliferative pro-
perties can be rationalised in terms of the fact that the
enzyme is a pivotal regulator of cell growth and
differentiation. Thus its inhibition is likely to cause interrup-
tion- of signal transduction pathways vital for cellular sur-
q" r" - o k I
l I
Figure 5 Western blot analysis of nPKC-e (a) and quantitation
by laser densitometry of nPKC-s protein (b) in cellular fractions
of naive A549 cells and of cells which have been incubated for
30 min with TPA (25 nM), staurosporine, UCN-01, RO 31-8220,
GF 109203X (each 0.1 or 1.0JAM), or CGP 41251 (I gmM). Cells
were separated into cytosolic (C), particulate (P) and nuclear (N)
fractions. Arrow indicates positions of nPKC-s. Values in b,
which are expressed as percentage of the sum of immunoreactive
protein in all three fractions, are the mean ± s.d. of 3-6 separate
blots. Stars indicate that the difference between control and
exposed cells is significant (P<0.05). nPKC-e levels in subfrac-
tions of cells which were incubated with calphostin C (0.5JAM),
H-7, H-71 (500iJM each) or miltefosine (200JuM) were not
different from those observed in control cells (results not shown).
For details of the assay see the Materials and methods section.
For abbreviations see legend to Figure 1.
vival. Nevertheless the experimental basis for the notion that
inhibition of PKC activity is causally associated with ability
to arrest growth has been tenuous, particularly in view of the
fact that most so-called 'PKC inhibitors' possess only modest
specificity for PKC, or none at all. Some evidence for such a
link was provied by experiments on quercetin, staurosporine
(Hofmann et al., 1988) and the alkyllysophospholipid BM
41440 (Grunicke et al., 1989) in 3T3 fibroblasts, even though
these compounds are clearly promiscuous in their ability to
inhibit kinases. In these cells the dose-effect relationship
with regard to inhibition of PKC was found to be similar to
the dose-response curves for depression of replication.
In the study presented above two separate experimental
approaches were adopted, and the results do not support the
notion that there is a mechanistic link between inhibition of
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PKC and growth arrest. Firstly, there was no relationship
between the IC,0 values for inhibition of growth and of
kinase activity. The pattern discernible in Figure 2 probably
mirrors gross differences between agents in their affinity for
kinases in general, not only for PKC. Secondly, PKC-deplet-
ed cells were not less, but more, sensitive towards the
growth-inhibitory effect of the kinase inhibitors compared
with naive cells. If growth arrest caused by PKC inhibitors
was indeed mediated by the interruption of signal transduc-
tion mechanisms operating via PKC one would expect pro-
liferation of PKC-depleted cells to be less affected by these
agents than that of PKC-proficient cells. This puzzling find-
ing can perhaps be explained by the increased intracellular
availability of kinase inhibitors enabling them to interact
with other targets when PKC-o and -E are eliminated as
binding sites. An alternative explanation relates to the fact
that cellular targets of bryostatin 1 other than PKC have yet
to be defined. Bryostatin might up-regulate certain kinases,
which consequently can be more effectively inhibited in the
presence of staurosporine or its analogues. It is now recog-
nised that results obtained using agents such as bryostatin to
down-regulate PKC have to be interpreted with prudence as
the initial enzyme activation caused by them elicits numerous
intracellular events before loss of PKC. Irrespective of the
mechanism involved, our results hint at the possibility that
the combination of kinase inhibitors with PKC-down-regu-
lating agents such as bryostatin 1 may be of therapeutic
benefit.
The cells used in this study express cPKC-a, nPKC-c and
PKC-4 (Stanwell et al., 1994). Of these enzymes cPKC-ac and
nPKC-e were efficiently down-regulated by exposure to
bryostatin, whereas the 4-isoenzyme is resistant to down-
regulation by this agent (Stanwell et al., 1994). Therefore one
could surmise that it is inhibition of PKC-; which might
mediate the growth arrest caused by these agents irrespective
of cellular PKC-a and -a levels. This hypothesis seems
especially compelling in the light of the recent suggestion that
PKC-4 plays a critical role in the control ofmitogenic signal-
induced proliferative cascades downstream of p2lr'a (Berra et
al., 1993). However, PKC-g is unlikely to be involved with
the mechanism of growth inhibition as it seems to be vir-
tually unaffected by analogues of staurosporine, at least in
intact cells (Martiny-Baron et al., 1993). It is also noteworthy
that the effect of PKC down-regulation was essentially equal
in the two cell lines regardless of the fact that relative levels
of PKC-x and -e differ considerably between them (Stanwell
et al., 1994). As PKC is apparently not a primary mediator
of the cytostatic properties of kinase inhibitors in A549 and
MCF-7 cells, other kinases may be involved. One candidate
is p34c&2 kinase, which is inhibited by staurosporine almost
as strongly as PKC (Gadbois et al., 1992). Overall, the
observations described above cast doubt on the notion that
PKC-selective inhibitors are superior in their antineoplastic
properties to inhibitors of other kinases, an inference which
should be borne in mind in the search for novel kinase
inhibitors as anti-cancer drugs.
Staurosporine possesses a puzzling mixture of phorbol
ester agonistic and antagonistic properties (Dlugosz and
Yuspa, 1991). It inhibits PKC enzyme activity potently, but
also causes the subcellular translocation of nPKCs (Kiley et
al., 1992) and augments TPA-induced redistribution of phor-
bol ester binding sites (Bradshaw et al., 1992). The results
described above demonstrate for the first time an intriguing
difference between staurosporine and its analogues. UCN-01,
RO 31-8220 and GF 109203X mimicked staurosporine by
eliciting translocation of nPKC-e from the cytosol to the
membrane and nucleus, whereas CGP 41521 and the PKC
inhibitors structurally unrelated to staurosporine did not.
None of the agents enhanced TPA-induced cPKC-x redistri-
bution significantly. Restriction of nPKC-c redistributory
activity to staurosporine and selected cogeners suggests that
this phenomenon is mechanistically associated with inter-
action at the catalytic domain of the enzyme, where these
agents are thought to inhibit PKC (Tamaoki et al., 1986;
Takahashi et al., 1987; Toullec et al., 1991). In contrast,
calphostin C (Kobayashi et al., 1989) and miltefosine
(Uberall et al., 1991) act at the regulatory site. The finding
that H-7, which also acts at the catalytic site (Hidaka et al.,
1984), did not alter nPKC-c localisation may be a corollary
of its lower affinity for the enzyme compared with that of
staurosporine, UCN-01, RO 31-8220 and GF 109203X.
It seems pertinent to compare the concentrations required
to elicit nPKC-e redistribution with those at which these
compounds precipitate other biological effects, such as inhibi-
tion of PKC activity in vitro and arrest of cell growth. The
concentrations of UCN-01, RO 31-8220 and GF 109203X
which changed nPKC-e localisation significantly (0.1 pM)
exceed their IC50 values for PKC inhibition by factors of 3, 4
and 4 respectively. This difference suggests that PKC isoen-
zyme translocation, which is known to be a consequence of
enzyme activation, may also be caused by potent enzyme
inhibition. But then it is difficult to explain why CGP 41251,
a strong PKC inhibitor, was incapable ofcausing PKC trans-
location. Furthermore, in the case of staurosporine the
lowest nPKC-e-redistributory concentrations (1 and 10nM)
were only weakly inhibitory in the PKC activity assay. The
concentrations of staurosporine and UCN-01 required for
translocation are 2- to 3-fold higher than the IC50 values at
which they inhibited the growth ofA549 cells. Yet in the case
of RO 31-8220 and GF 109203X concentrations with anti-
proliferative efficacy are bound to elicit appreciable trans-
location of nPKC-s.
One of the aims of this study was to explore any relation-
ship between structure and activity among staurosporine and
four of its analogues with respect to their effects on cell
growth and on PKC. In both cell types the order of growth-
inhibitory potency was staurosporine > UCN-01 > CGP
41251 >RO 31 8220 >GF 109203X. The order of their
enzyme-inhibitory efficacy was RO 31-8220 = GF 109203X =
UCN-01 > staurosporine = CGP 41251 with PKC obtained
from A549 cells, and staurosporine = UCN-01 = GF
109203X > RO 31 8220 = CGP 41251 with PKC from MCF-
7 cells. Intriguingly, CGP 41251 is a strong inhibitor of both
cell growth and PKC activity, but incapable of eliciting
nPKC-e translocation. In contrast, UCN-01 interfered
strongly with growth and PKC activity and also altered
nPKC-c localisation, whereas RO 31-8220 and GF 109203X
are efficacious enzyme inhibitors and caused nPKC-c redist-
ribution, yet they are rather poor inhibitors of cell growth.
These differences in potency allow tentative interpretation of
the complicated structure-activity relationships which govern
the abilities of these compounds to affect PKC and cell
growth. The indolocarbazole staurosporine inhibited PKC
and growth with high potency. These properties are not
adversely affected by the addition of a hydroxy group at
carbon 7 of the aglycone part (UCN-01), or of a benzoyl
moiety on the nitrogen in position 4' of the glycone part of
the staurosporine molecule (CGP 41251) (see Figure 1). Yet
the presence of N-benzoyl abolishes its nPKC-s trans-
locatory efficacy. The change from the indolocarbazole to the
bisindolylmaleimide structural skeleton, that is from stauros-
porine to RO 31-8220 and GF 109203X, retains the ability to
inhibit PKC and to translocate nPKC-e, but diminishes
strongly the growth-inhibitory potential of the molecule.
In conclusion, this study suggests that PKC does not play
a direct role in the mechanisms by which PKC inhibitors
arrest the growth of A549 and MCF-7 carcinoma cells. Fur-
thermore, it seems that for a PKC inhibitor to affect sub-
cellular enzyme localisation it has to be an analogue of
staurosporine which possesses a high affinity for PKC. Fur-
ther studies on these compounds will help to understand the
mechanism by which they interfere with cell growth and
perhaps point to other constituents of signal-transducing
kinase cascades as suitable targets in the development of
novel drugs.
Abbreviations: ICs,o 50% inhibitory concentration; cPKC,
conventional (Ca2"-dependent) protein kinase C; nPKC,
novel (Ca2"-independent) protein kinase C; [3H]Tdr, [methyl-
[3H]thymidine; TPA., 12-0-tetradecanoyl phorbor-13-acetate.
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